pSivida Corp (PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced it has been issued US patent No. 8,192,408 titled “Ocular Trocar Assembly” for a new inserter developed to facilitate administration of micro-drug delivery devices.
“We are very pleased with the issuance of this US patent for our new inserter,” said Dr. Paul Ashton, president and CEO of pSivida. “We have designed it to allow the insertion of drug delivery devices, such as our MedidurTM implant, through a far smaller needle than was previously possible and to require significantly less force to administer. We anticipate using this new inserter in the planned Phase III trials of our posterior uveitis insert. “Another advantage,” Dr. Ashton continued, “is that the new inserter allows for use of larger reservoir delivery devices. Thus our Durasert technology can now be used with a larger number of drugs”.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, DurasertTM and BioSiliconTM. ILUVIEN® for the treatment of Diabetic Macular Edema (DME), which is licensed to Alimera Sciences, Inc., is pSivida’s most advanced product candidate, and based on a consensus arrived upon by the RMS and the CMS, the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) issued its Final Assessment Report that ILUVIEN for chronic DME is approvable.